Preparation, characterization and in vitro cytotoxicity evaluation of docetaxel nanoparticles against A549 cell line
Authors
Abstract:
Introduction: Docetaxel (DTX) is one of the most potent anticancer drugs in the taxane family. The commercial formulation of DTX for clinical use consists of high concentrations of tween80, which has been caused serious patient`s difficulties. Therefore, preparation of novel drug delivery system with ability of removing tween 80 and targeting on cancer tissue can lead more effective and also decrease side effects. This study is focused on preparation, characterization and cytotoxicity evaluation of docetaxel and poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) against a tumor cell line. Materials and Methods: NPs of DTX and PLGA was prepared by a modified emulsification/solvent diffusion method. Then the obtained NPs were characterized and evaluated. For this purpose, 10000 viable cells were seeded in each well of 96-well plate and after 24 hours of incubation different concentrations of conventional and NPs were added to the wells. Then mitochondrial dehydrogenase activities in living cells were determined at 24, 48 and 72 hours by MTT assay. Results: The average diameter of the NPs was approximately 184.3 ± 14.6 nm with poly dispersity index of 0.15. Notably, the results showed significant increase in cytotoxicity of the NPs against the A549 cell line. Inhibitory concentration (IC50) of free drug and NPs was 20.66 ± 0.22, 18.27 ± 0.45, 10.64 ± 0.38 and 0.57 ± 0.04, 0.16 ± 0.04, 0.07 ± 0.01 (µg/ml) at 24, 48 and 72 hours respectively. Conclusion: This study demonstrates the higher cytotoxicity of DTX-PLGA NPs on human lung cancer cell line. The present formulation can be considered for the further studies on other cell lines and in vivo evaluation.
similar resources
Comparative of in vitro evaluation between erlotinib loaded Nanostructured lipid carriers and liposomes against A549 lung cancer cell line
Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP),...
full textComparative of in vitro evaluation between erlotinib loaded Nanostructured lipid carriers and liposomes against A549 lung cancer cell line
Erlotinib (ELT) as a small molecule with poor solubility, poor bioavailability, and instability in gastrointestinal environment, has been considered as a therapeutic agent for Non-Small-Cell Lung Cancer (NSCLC) therapy through oral administration. In the present study, ELT-liposome and ELT-NLCs were successfully prepared and characterized by assessment of the particle size, zeta potential (ZP),...
full textBiodegradable preparation, characterization and In vitro evaluation of stealth docetaxel lipid nanoemulsions for efficient cytotoxicity
1Nanotechnology Laboratory, Department of Pharmaceutics, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Andhra Pradesh, India 506009 A b s t r a c t Docetaxel is currently used in treatment of breast and ovarian cancers, administered in the form of parenteral IV infusion. Lipid nanoemulsion (LNE) delivery system is biocompatible, biodegradable and easy to prepare....
full textEffect of Clarithromycin on Enhancement of Doxorubicin-induced Cytotoxicity and Apoptosis in A549 Tumor-Cell Line
Background and purpose: Nowadays, multi-drug regimens or combination therapy are new approaches in cancer treatment that combine two or several therapeutic agents. Combination therapy aims at improving the therapeutic efficacy of anticancer drugs while reducing toxicity and preventing drug resistance. The aim of this study was to determine the synergistic effect of combined clarithromycin and d...
full textMy Resources
Journal title
volume 21 issue 2
pages 340- 346
publication date 2019-04
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023